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found. Compared with the LA group, more patients in the AD 
group, were treated with IMRT; 17% vs. 6% (p<0.01), and 
nodal boost - 22% vs. 13% (p <0.01). For brachytherapy, more 
patients in the AD group were treated with HDR BT; 66% vs. 
52% (p<0.01), combined IC/IS technique - 47% vs. 4% 
(p<0.01), and MRI based dose planning - 97% vs. 66% 
(p<0.01).Compared with the LA group, average HR CTV 
volume was 6cm3 larger and average D90 for HR CTV was 9 Gy 
higher in the AD group (p<0.01). This target dose difference 
did not result in higher D2cm³, for rectum (p=0.12) or 
sigmoid (p=0.38) in the AD group. D2cm³ for bladder was on 
average 4 Gy lower in the AD group (p=0.07) (table 1). 
At a median follow-up of 40 (3-163) months no significant 
difference in late actuarial grade 2 to 5 bladder (p=0.63), 
gastro-intestinal (p=0.81) or vaginal morbidity (p=0.10) was 
found between the LD and AD groups. 
 
 
Conclusions: Advanced adaptation with combined IC/IS 
technique enables delivery of significantly higher radiation 
doses to the HR CTV D90 without increasing the D2cm³ to 
organs at risk or adding more late morbidity to treatment.  
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Purpose/Objective: In our department, an adaptive 
radiotherapy protocol is used for laryngeal cancer patients 
treated with IMRT on the larynx as well as the bilateral 
(elective) lymph nodes. The goal was to investigate the 
clinical feasibility and the impact of this protocol.  
Materials and Methods: Twenty-seven patients were 
included. During fraction 1-4 in week 1, and in three 
fractions in the weeks thereafter, a CBCT was acquired. For 
each CBCT, an automatic gray value registration based on a 
clipbox around the cervical vertebrae was performed using 
the Elekta XVI software (version 4.5.1). Setup corrections 
were performed following the extended No Action Level 
(eNAL) protocol1. Technologists evaluated the position of the 
larynx relative to the PTV and the laryngeal bony structures, 
after the correction based on the vertebrae. If a 
displacement of 5 mm or more was seen, the physician was 
contacted to decide whether or not a new planning CT-scan 
and adaptive re-planning were required (CTV-PTV margin of 5 
mm). The impact of this protocol on larynx set-up variations 
and resulting margins were assessed.  
Results: In a recent study2 it was demonstrated that due to 
non-rigid motion in larynx cancer patients, applying the eNAL 
protocol with once a week follow-up imaging and omitting 
the above described approach for plan adaptation, a 5 mm 
CTV-PTV margin for the larynx was not sufficiently large in 
the cranial-caudal (CC) direction (see Table 1). In the new 
protocol, apart from three times a week imaging and 
adaptive re-planning, the patients also got swallowing 
instructions during CT, CBCT and irradiation. For 11/27 
patients one or more new planning CTs were made. This 
resulted in smaller calculated margins than in the previous 
study (Table 1). 
Table 1: Population mean (m), random (s), and systematic (S) 
set-up errors and calculated CTV-PTV margins3. 
 
 eNAL (2012)2  eNAL + adaptive re-
planning (2014) 
LR(mm) CC(mm) AP(mm) LR(mm) CC(mm) AP(mm) 
µ  -0.3 0.3 0.8 -0.3 -0.4 0.4 
σ  2.0 2.8 2.0 1.2 2.6 1.9 
∑ 0.9 2.8 1.0 0.8 1.6 1.0 
Margin33.2 7.6 3.5 2.4 5.0 3.2 
 
Conclusions: Based on a clear decision protocol for the 
technologists, adaptive treatment of laryngeal cancer 
patients was successfully implemented in the clinical routine. 
The approach effectively reduced CTV-PTV-margins. New 
patients are currently being entered in the study and will be 
included in the final analyses. 
1. IJROBP 2007, 1586–1595 
2. IJROBP 2013, 401-406 
3. IJROBP 1999, 905-919  
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Purpose/Objective: Large changes in bladder shape and size 
during a course of radiotherapy (RT) make adaptive RT (ART) 
appealing in the treatment of this tumor site. We are 
conducting a multi-center clinical phase II trial of daily plan 
selection based ART for bladder cancer with the primary aim 
of reducing gastro-intestinal morbidity due to sparing of the 
bowel and the rectum. We here report early dose/volume 
outcomes from the first twenty patients treated in this trial. 
Materials and Methods: All twenty patients received 60 Gy in 
30 fractions to the bladder; in 13 of the patients the pelvic 
lymph nodes were simultaneously treated to 48 Gy. Cone-
beam CT (CBCT) image guidance was used for daily set-up 
and treatment was delivered by volumetric modulated arc 
therapy (VMAT). The first five fractions were delivered using 
large, population-based margins; the bladder contours from 
the CBCTs acquired prior to the first four fractions were used 
to create a library of three plans, corresponding to a small, 
medium and large size bladder. All patients were from 
fraction no. 6 treated using daily online plan selection, where 
the smallest plan covering the bladder was selected prior to 
each treatment delivery. Volume ratios of PTV for ART vs. 
non-ART averaged over the treatment course were 
calculated. DVHs for bowel cavity and rectum were derived 
by summation of the selected dose plans on the planning CT 
and these were compared to standard non-adaptive RT plans 
using population-based margins (20 mm Sup/Ant, 15 mm Post 
and 10 mm LR and Inf). 
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Results: The frequencies of which the small, medium and 
large size plans were used over the (total of 600) fractions 
were similar; plans were used at a median of 9, 9.5 and 10 
fractions respectively. The median volume ratio of PTV-ART 
vs. non-ART across the treatment course was 0.70 (range: 
0.46-0.89). The median rectal volume receiving 50 Gy or 
more was 5% (range: 0-41%), compared to 17% (range: 0-62%) 
if the patients had been treated with standard, non-adaptive 
RT (Fig 1). For the bowel cavity, the median volume receiving 
more than 45 Gy was 392 cm3 (range: 84-625 cm3), compared 
to 487 cm3 (range: 126-710 cm3) if not treated with 
adaptation (Fig 1). 
Conclusions: Daily adaptive plan selection in RT of bladder 
cancer results in a considerable normal tissue sparing, which 
is expected to reduce the risk of gastro-intestinal morbidity. 
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Medical physicists contribute to maintaining and improving 
quality, safety and cost-effectiveness of healthcare services 
through patient-oriented activities requiring expert action, 
involvement or advice regarding the specification, selection, 
acceptance testing, commissioning, quality assurance/control 
and optimised clinical use of medical radiological devices. 
Medical physicists working in a clinical environment are 
healthcare professionals and those at the highest level (level 
8 on the European qualifications framework)are Medical 
Physics Experts(MPEs) competent to practice independently 
in one or more of the subfields (specialties) of medical 
physics; in this way the MPE has the capabilities to tackle 
clinical problems through strategic multidisciplinary 
approaches.  
Today the multidisciplinary approach with medical physicists 
in the clinical environment together with those in the 
commercial industry as well as university research areas is 
mandatory where dosimetry, dosimetric calculation and 
medical imaging for planning and verification needs to be 
approached with a number of different competences. 
Collaboration on clinical research projects between 
commercial partners and medical physicists/MPE should 
therefore be encouraged at all levels. 
Academic partners have the capabilities to develop new 
applications of physics in medicine (linear accelerators, new 
detectors, Monte Carlo simulations, etc.) and have the 
competences required to support such developments. The 
experience derived from protosyncrotony and ion and 
particle accelerator developments in particle research has 
provided fundamental experience to understand what the 
correct approach needs to be to tackle the clinical 
applications.  
Companies have the role to develop hardware and software 
devices for radiotherapy but need medical physics 
competences for testing and optimization "on the field". Many 
advanced medical physics departments are "beta-site" for 
different applications. Pre-release software for treatment 
planning, new treatment modalities, image processing and 
registration technique for Adaptive planning , integrated 
MRI/linear accelerator and high intensity focused ultrasound 
(HIFU) in oncology therapy are typical examples where a 
multidisciplinary approach is essential. A PACS solution for 
radiotherapy is another examples where medical physicists 
are able to define the functional differences between the 
PACS required for radiotherapy compared with the 
requirements for conventional radiology PACS.  
New software for image integration and registration 
techniques must first be validated in clinical practice and the 
multidisciplinary medical physics department is an essential 
partner for companies to create optimized protocols for 
clinical use. 
Finally the medical physicist/MPE is frequently involved in 
training activities  and these experts can also be used to 
inform companies on their development profiles. 
The use of webinar will provide further opportunities for the 
cooperation and training for all the actors involved in 
radiotherapy. 
In conclusion, in order to ensure  that the quality of patient 
treatments is maintained and further improved while  the 
risk of errors is reduced it is necessary that all these 
activities are to be carried out in the clinical working 
environment. In addition many of these activities require 
further development and improvement  within a research 
environment  parallel to the clinical work. 
However, staff often have to carry out research and 
development outside normal working hours due to lack of 
time. This situation is not sustainable and could finally result 
in unsafe patient treatments. It must be realized that 
medical physics departments should have at least an 
additional 0.3 whole time equivalent staffing complement 
(ref. European Guidelines on Medical Physics Expert (Annex 
2)) to carry out these important research and development 
activities. 
References: European Guidelines on Medical Physics Expert, 
Annex 2, Radiation Report No174, European Commission, 
2014  
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In the past decade the introduction of new technologies such 
as IMRT has given a strong boost to medical physics and the 
field of radiation oncology in the US. In the period from 2003 
until 2009 alone, the expenditure for radiation oncology has 
